Autor: Andreas Teufel

M.P. Roberti and C. Rauber aim to investigate the influence of gut microbiota-derived metabolites on CRC metastasis with a special focus on their modulation of tumour intrinsic pathways of immune recognition. Previously, M.P. Roberti and C. Rauber have demonstrated in preclinical models that response of microsatellite stable (MSS) CRC to immune checkpoint inhibitors (in combination …

Mehr über „Project 4: Roberti/Rauber – Microbial metabolites & tumor immunogenicity“ Lesen

The functional implications of the intra-metastasis microbiome are also largely unknown. For this reason, L. Hinze and J. Puschhof hypothesise that the interplay of microbiota-derived factors and metabolic changes influences niche dependency, metastasis phenotypes and thereby therapy response in CRC metastases. Previously, they identified ribosomal proteins of the large and small subunits as drivers of …

Mehr über „Project 3: Hinze/Puschhof – Microbes, metabolism“ Lesen

E. Burgermeister and G. Zeller will build on these spatial studies to reconstitute the key associations discovered in situ using PDO models from primary CRC tumours and metastases. This shall enable mechanistic dissection of microbe-host crosstalk and its impact on the efficacies of chemo- and targeted therapies, paving the way for future microbiome-aware personalised oncology approaches to …

Mehr über „Project 2: Burgermeister/Zeller – Tumor resident microbiota“ Lesen

T. Zhan and M. Zimmermann-Kogadeeva propose to combine their complementary expertise in microbiome research and translational oncology to identify and characterise novel links between gut microbiome drug metabolism and response to cancer therapy in CRC. They propose to assess the gut microbiome contribution to the metabolism of fluoropyrimidines and multi-kinase inhibitors by integrating results from …

Mehr über „Project 1: Zhan/Zimmermann-Kogadeeva – Microbiota drug metabolism“ Lesen